Patients whose only complaint is weight and who have no secondary concerns about skin, hair, inflammation, or tissue quality are better served by optimizing their GLP-1 protocol, adding resistance training, and addressing nutrition rather than adding a peptide that doesnt directly address their primary goal
10.1111/j.1365-313X.2008.03756.x Plant J
Bowtie2 was used to build the genome index, and the RNA-seq data were then aligned to the reference genome using HISAT2
The peptide half-life chart values above represent midpoint consensus estimates from multiple sources and should be treated as starting-point references rather than definitive figures
Increases in resting heart rate are a recognised class effect of incretin-based therapies and have been reported with GLP-1 receptor agonists more broadly, as reflected in the Summary of Product Characteristics (SmPC) for licensed agents such as semaglutide (Wegovy) and liraglutide (Saxenda)